{
    "nctId": "NCT05231863",
    "briefTitle": "Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study",
    "officialTitle": "Tyrosine Kinase Inhibitors (TKIs) Based Therapy in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Progression Free Survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female and 18-70 years old\n* Metastatic or locally recurrent HER2-positive breast cancer\n* Patients received TKIs-based therapy after T-DM1 failure in treatment for metastasis\n* Complete and accurate medical data\n\nExclusion Criteria:\n\n- Incomplete medical data",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}